{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:27:01Z","timestamp":1793273221473,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.survophthal.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T12:41:41Z","timestamp":1644928901000},"page":"1419-1442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Dupilumab-associated ocular manifestations: A review of clinical presentations and management"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2247-0949","authenticated-orcid":false,"given":"Duoduo","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin S.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-9524","authenticated-orcid":false,"given":"Andre J.X.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn K.A.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedee F.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-5046","authenticated-orcid":false,"given":"Blanche X.H.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6362-4898","authenticated-orcid":false,"given":"Jodhbir S.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2219-3184","authenticated-orcid":false,"given":"Chris H.L.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2022.02.002_bib0001","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/all.14080","article-title":"Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the bioday registry","volume":"75","author":"Ari\u00ebns","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0003","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0004","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0005","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/ijd.15584","article-title":"Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: A bicentric retrospective comparative cohort study","volume":"60","author":"Barb\u00e9","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0006","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ajoc.2017.06.017","article-title":"Cicatricial ectropion in a patient treated with dupilumab","volume":"7","author":"Barnes","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0007","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0008","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.iac.2010.06.004","article-title":"Atopic dermatitis and keratoconjunctivitis","volume":"30","author":"Bielory","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0009","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (liberty ad chronos): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/ICO.0000000000002461","article-title":"Dupilumab-associated ocular surface disease: Clinical characteristics, treatment, and follow-up","volume":"40","author":"Bohner","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0011","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1398-9995.1993.tb00711.x","article-title":"Heterogeneity of atopy. I. Clinical and immunologic characteristics of patients allergic to cypress pollen","volume":"48","author":"Bousquet","year":"1993","journal-title":"Allergy"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1081-1206(10)60853-8","article-title":"Pulmonary complications of common variable immunodeficiency","volume":"98","author":"Busse","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"85","key":"10.1016\/j.survophthal.2022.02.002_bib0013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1398-9995.2007.01549.x","article-title":"A survey of the burden of allergic rhinitis in europe","volume":"62","author":"Canonica","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0014","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1869-5760-3-12","article-title":"Ox40 ligand expression abrogates the immunosuppressive function of retinal pigment epithelium","volume":"3","author":"Cunningham","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0016","first-page":"532","article-title":"Dupilumab (dupixent)","volume":"43","author":"D'Ippolito","year":"2018","journal-title":"Pharm Ther"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0017","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/ajd.12292","article-title":"Ocular side-effects of topical corticosteroids: What a dermatologist needs to know","volume":"56","author":"Daniel","year":"2015","journal-title":"Aust J Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0018","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jdcr.2019.07.020","article-title":"Dupilumab facial redness: Positive effect of itraconazole","volume":"5","author":"de Beer","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0019","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0020","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjd.18179","article-title":"Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: Daily practice data","volume":"182","author":"de Wijs","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0021","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0022","first-page":"301","article-title":"Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in crswnp","volume":"59","author":"Desrosiers","year":"2021","journal-title":"Rhinology"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0023","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/archopht.120.9.1180","article-title":"Docetaxel secretion in tears: Association with lacrimal drainage obstruction","volume":"120","author":"Esmaeli","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0024","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life french multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0025","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/09546634.2019.1682503","article-title":"Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis","volume":"32","author":"Fargnoli","year":"2021","journal-title":"J Dermatol Treat"},{"issue":"1","key":"10.1016\/j.survophthal.2022.02.002_bib0026","first-page":"A85","article-title":"4cps-039 dupilumab treatment discontinuation due to limiting adverse effects: A case report","volume":"26","author":"Ferreras","year":"2019","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0027","first-page":"1152","article-title":"Amelioration of conjunctival giant papillae by dupilumab in patients with atopic keratoconjunctivitis","volume":"8","author":"Fukuda","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0028","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.alit.2018.12.012","article-title":"Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis","volume":"68","author":"Fukuda","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0029","first-page":"21","article-title":"Ocular complications of atopic dermatitis","volume":"19","author":"Garrity","year":"1984","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0030","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1111\/jdv.16278","article-title":"Dupilumab therapy in a patient with atopic dermatitis and severe atopic keratoconjunctivitis","volume":"34","author":"Gkalpakiotis","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0031","first-page":"298","article-title":"Atopic dermatitis is associated with increased prevalence of multiple ocular comorbidities","volume":"7","author":"Govind","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0032","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.1416922112","article-title":"Il-4 abrogates T(h)17 cell-mediated inflammation by selective silencing of il-23 in antigen-presenting cells","volume":"112","author":"Guenova","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.survophthal.2022.02.002_bib0033","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jfo.2010.07.004","article-title":"Cicatricial conjunctivitis","volume":"33","author":"Gueudry","year":"2010","journal-title":"J Fr D'ophtalmol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0034","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/ACI.0b013e32833e16e4","article-title":"Atopic keratoconjunctivitis and atopic dermatitis","volume":"10","author":"Guglielmetti","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0036","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0037","doi-asserted-by":"crossref","first-page":"e13222","DOI":"10.1111\/dth.13222","article-title":"Dupilumab for prurigo nodularis: Case series and review of the literature","volume":"33","author":"Holm","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0038","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2340\/00015555-3121","article-title":"Eye complications during dupilumab treatment for severe atopic dermatitis","volume":"99","author":"Ivert","year":"2019","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0039","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0040","article-title":"Psoriasis appearing after dupilumab therapy in atopic dermatitis: A case report","volume":"8","author":"Kim","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0041","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000334286","article-title":"The burden associated with ocular symptoms in allergic rhinitis","volume":"158","author":"Klossek","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0042","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/09546634.2019.1711010","article-title":"Punctal stenosis associated with dupilumab therapy for atopic dermatitis","volume":"32","author":"Lee","year":"2021","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0043","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00417-006-0285-7","article-title":"Th1- and th2-type cytokines in chronic ocular allergy","volume":"244","author":"Leonardi","year":"2006","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0044","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","article-title":"Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management","volume":"154","author":"Levine","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0045","article-title":"Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis","volume":"19","author":"Li","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0046","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/ICO.0000000000002262","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"39","author":"Liberman","year":"2020","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0047","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2018.07.043","article-title":"Dupilumab use in allergic contact dermatitis","volume":"80","author":"Machler","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0048","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0049","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/DER.0000000000000461","article-title":"Blepharoconjunctivitis secondary to dupilumab successfully treated with itraconazole","volume":"30","author":"McCarthy","year":"2019","journal-title":"Dermatitis"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0050","first-page":"275","article-title":"Dupilumab induced limbal stem cell deficiency","volume":"14","author":"Mehta","year":"2021","journal-title":"Int Med Case Rep J"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0051","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (diosd) in patients with atopic dermatitis: Clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0052","first-page":"01119","article-title":"Management of inadequate response and adverse effects to dupilumab in atopic dermatitis","volume":"21","author":"Narla","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0053","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.anai.2010.08.020","article-title":"Allergic conjunctivitis in asthmatic children: As common as underreported","volume":"105","author":"Neto","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0054","doi-asserted-by":"crossref","first-page":"201","DOI":"10.18176\/jiaci.0481","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis: A multicenter real-life experience","volume":"30","author":"Nettis","year":"2020","journal-title":"J Invest Allergol Clin Immunol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0055","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaip.2019.10.015","article-title":"Dupilumab-induced bilateral cicatricial ectropion in real life","volume":"8","author":"Nettis","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0056","article-title":"A review of clinical disease scoring systems for cicatricial diseases of the conjunctiva","volume":"8","author":"Ong","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0057","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jtos.2019.10.010","article-title":"Validation of a clinical assessment tool for cicatrising conjunctivitis","volume":"18","author":"Ong","year":"2020","journal-title":"Ocul Surf"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0058","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15140","article-title":"Dupilumab facial redness: Clinical characteristics and proposed treatment in a cohort","author":"Ord\u00f3\u00f1ez-Rubiano","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0059","first-page":"1","article-title":"Association of dupilumab with intraocular inflammation","author":"Padidam","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0060","article-title":"Dupilumab-associated blepharoconjunctivitis","volume":"16","author":"Paulose","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0061","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1038\/s41433-020-01379-9","article-title":"Dupilumab-associated ocular surface disease: Presentation, management and long-term sequelae","volume":"35","author":"Popiela","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0062","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3390\/jcm9041241","article-title":"Dupilumab for the treatment of atopic dermatitis in an austrian cohort-real-life data shows rosacea-like folliculitis","volume":"9","author":"Quint","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0063","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0064","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijwd.2019.08.007","article-title":"Nonsteroid management of residual ocular surface disease on dupilumab (ROSDD)","volume":"5","author":"Raffi","year":"2019","journal-title":"Int J Women's Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0065","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ijwd.2019.10.001","article-title":"Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD)","volume":"5","author":"Raffi","year":"2019","journal-title":"Int J Women's Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0066","doi-asserted-by":"crossref","first-page":"e12931","DOI":"10.1111\/dth.12931","article-title":"Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series","volume":"32","author":"Ruiz-Villaverde","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0067","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1016\/j.ijid.2012.11.022","article-title":"Evaluation of the efficacy of oral ivermectin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of demodex folliculorum","volume":"17","author":"Salem","year":"2013","journal-title":"Int J Infect Dis"},{"issue":"85","key":"10.1016\/j.survophthal.2022.02.002_bib0068","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1398-9995.2007.01548.x","article-title":"A survey of the burden of allergic rhinitis in the USA","volume":"62","author":"Schatz","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0069","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the ocular surface disease index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0070","doi-asserted-by":"crossref","first-page":"e13134","DOI":"10.1111\/dth.13134","article-title":"Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin","volume":"32","author":"Sernicola","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0071","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/09273948.2018.1533567","article-title":"Dupilumab-induced follicular conjunctivitis","volume":"27","author":"Shen","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0072","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Simpson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0073","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0074","first-page":"278","article-title":"Demodex musculi infestation in genetically immunomodulated mice","volume":"66","author":"Smith","year":"2016","journal-title":"Comp Med"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0075","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2147\/OPTH.S31904","article-title":"Punctal stenosis: Definition, diagnosis, and treatment","volume":"6","author":"Soiberman","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0076","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.chom.2019.02.002","article-title":"The skin commensal yeast malassezia triggers a type 17 response that coordinates anti-fungal immunity and exacerbates skin inflammation","volume":"25","author":"Sparber","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0077","first-page":"781","article-title":"Allergic contact dermatitis from tea tree oil","volume":"47","author":"Stonehouse","year":"2007","journal-title":"Consultant"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0078","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/1721727X17703271","article-title":"Differentiation of t-helper cells in distinct phases of atopic dermatitis involves th1\/th2 and th17\/treg","volume":"15","author":"Su","year":"2017","journal-title":"Eur J Inflamm"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0079","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jdcr.2018.08.027","article-title":"The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy","volume":"4","author":"Suresh","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0080","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0081","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/bjd.16330","article-title":"Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with demodex and increased interleukin-17 levels?","volume":"178","author":"Thyssen","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0082","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","article-title":"Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis","volume":"77","author":"Thyssen","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0083","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jdv.16724","article-title":"Incidence and risk factors for dupilumab associated ocular adverse events: A real-life prospective study","volume":"35","author":"Touhouche","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0084","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0085","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.18163","article-title":"Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in japanese patients: A single-centre retrospective study","volume":"181","author":"Uchida","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0086","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bjo.82.1.82","article-title":"Systemic and local immunological features of atopic dermatitis patients with ocular complications","volume":"82","author":"Uchio","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0087","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/bjo.2009.173419","article-title":"Expression of the interleukin-4 receptor alpha in human conjunctival epithelial cells","volume":"94","author":"Ueta","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0088","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/jdv.15914","article-title":"Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis","volume":"34","author":"Voorberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0089","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/ijd.14573","article-title":"Real-world experience of dupilumab treatment for atopic dermatitis in adults: A retrospective analysis of patients' records","volume":"59","author":"Wang","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0090","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/978-1-4615-0717-8_149","article-title":"Ocular drying associated with oral antihistamines (loratadine) in the normal population-an evaluation of exaggerated dose effect","volume":"506","author":"Welch","year":"2002","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0091","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0092","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s13555-020-00456-x","article-title":"Patient-reported ocular disorders and symptoms in adults with moderate-to-severe atopic dermatitis: Screening and baseline survey data from a clinical trial","volume":"10","author":"Weyne","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0093","first-page":"1778","article-title":"Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment","volume":"6","author":"Wollenberg","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0094","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01676830.2018.1553190","article-title":"Two differing presentations of periocular dermatitis as a side effect of dupilumab for atopic dermatitis","volume":"38","author":"Yamane","year":"2019","journal-title":"Orbit"},{"key":"10.1016\/j.survophthal.2022.02.002_bib0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jdcr.2018.10.016","article-title":"Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report","volume":"5","author":"Zirwas","year":"2019","journal-title":"JAAD Case Rep"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625722000303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625722000303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:54:58Z","timestamp":1758542098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625722000303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0039625722000303"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2022.02.002","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab-associated ocular manifestations: A review of clinical presentations and management","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2022.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}